Sotio Biotech

Sotio Biotech is a clinical-stage immuno-oncology company headquartered in Prague, Czech Republic. Our robust clinical pipeline includes differentiated superagonists targeting the attractive immuno-oncology target IL-15, proprietary technologies designed to enhance the efficacy of CAR T-cell therapies, and next-generation highly effective and stable antibody-drug conjugates (ADCs). SOTIO is developing next-generation potent immunotherapies for cancer patients. To achieve this goal, we plan to acquire therapeutic oncology assets in late preclinical or clinical stages to incorporate into our portfolio. We are seeking differentiated drugs in various modalities (small molecules, biologics, cell therapies, etc.) that have the potential to make a real impact on cancer patients.